B of A Securities Rates Avalo Therapeutics (AVTX) buy

B of A Securities Maintains Bullish Stance on Avalo Therapeutics

B of A Securities analyst Alec Stranahan reaffirmed a Buy rating on Avalo Therapeutics, Inc. (AVTX) on June 12, 2026. The firm set a price target of $35.00, signaling confidence in the company's clinical pipeline. This rating comes as the company continues to advance its lead candidate, AVTX-009, through Phase 2 clinical trials. The $35.00 target is substantially higher than where the stock has traded recently, though it sits below the even more aggressive targets set by some other Wall Street firms.

Avalo Therapeutics Stock Performance and Valuation

Shares of Avalo Therapeutics were priced at $14.33 on Saturday. The stock has experienced a volatile year, ranging from a low of $10.70 to a high of $24.27 over the last 52 weeks. At its current price, the stock is trading under its 200-day moving average of $16.87 and its 50-day moving average of $18.70. Because the company is still in the clinical stage and not yet profitable, it does not have a meaningful P/E ratio, but it carries a debt-to-equity ratio of just 0.054.

Recent Earnings and Financial Position

Avalo Therapeutics reported revenue of $59,000 in its most recent filing period. The company has an earnings per share (EPS) of -$4.41, which is common for biotech firms focused on research and development rather than immediate sales. Despite the losses, Avalo maintains a high current ratio of 19.306, suggesting it has enough cash and short-term assets to cover its immediate obligations. Investors are looking toward November 12, 2026, for the next scheduled financial update.

Analysts Set New Price Targets

Beyond the latest note from B of A Securities, other analysts have also updated their views on the stock recently. On August 7, 2026, Guggenheim maintained its Buy rating but slightly lowered its price target from $50.00 to $48.00. That same day, HC Wainwright & Co. also kept its Buy rating while trimming its target from $35.00 to $30.00. Earlier in the summer, on July 6, 2026, Leerink Partners started coverage on the stock with an Outperform rating and a $38.00 price target. Across 12 analysts, the consensus remains a Strong Buy with a mean price target of $44.08.

Focus on Immune-Mediated Diseases

Avalo Therapeutics is a biotechnology company based in Wayne, Pennsylvania, that focuses on developing treatments for inflammatory diseases. Its primary work centers on AVTX-009, a monoclonal antibody designed to bind to interleukin-1β, a protein involved in the body's inflammatory response. The company rebranded from Cerecor Inc. in 2021 to better align with its focus on these targeted therapies.

Looking Ahead for AVTX

The reiteration from B of A Securities suggests that professional observers are staying the course as Avalo moves through the expensive and complex clinical trial process. While the $35.00 target is optimistic compared to the current market price, the stock's future likely depends on the data readouts from its ongoing Phase 2 trials. Investors should keep an eye on the November earnings date and any further SEC filings for updates on the company's cash runway and clinical milestones.